Treatment News : Sustiva (Efavirenz) Linked to Doubled Risk of Suicidality

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 16, 2014

Sustiva (Efavirenz) Linked to Doubled Risk of Suicidality

People with HIV starting treatment regimens containing Sustiva (efavirenz) have a more than doubled risk of suicidal thoughts, attempts and completed attempts, when compared with those beginning Sustiva-free regimens, MedPage Today reports. Publishing their findings in the Annals of Internal Medicine, researchers examined data on 5,332 initially treatment-naive HIV-positive members of four different AIDS Clinical Trials Group studies.

The participants were randomly assigned to begin antiretroviral (ARV) regimens either with Sustiva (3,241 participants) or without (2,091 participants). The median follow-up time was 96 weeks.

The study defined suicidality as suicidal thoughts, or attempted or completed suicide. There were 47 participants who reported suicidality in the Sustiva group, for a rate of 8.08 per 1,000 person-years, compared with 15 participants who did so in the non-Sustiva group, for a rate of 3.66 per 1,000 person-years. Consequently, Sustiva was associated with a 2.28-fold increase in the rate of suicidality. Seventeen participants in the Sustiva group attempted or completed suicide, for a rate of 2.90 per 1,000 person-years, compared with five in the Sustiva-free group, for a rate of 1.22 per 1,000 person-years. Thus, those taking Sustiva had a 2.58-fold increased likelihood of attempted or completed suicide. A total of eight people in the Sustiva group committed suicide, compared with one in the Sustiva-free group.

The study is limited by the fact that there was no standard questionnaire about suicidal ideations or attempts. Also, three of the four studies were open label, meaning participants knew which drugs they were taking.  

To read the MedPage Today story, click here.

To read the study abstract, click here.

Search: Sustiva, efavirenz, suicidality, suicide, MedPage Today, AIDS Clinical Trials Group.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.